Our findings are consistent with these studies, as our pan-cancer analysis revealed high FJX1 expression in 22 types of cancer, and it was correlated with poor overall survival, disease-specific survival, disease-free interval, progression-free interval, and worse overall survival in some cancers. The gene discussed is FJX1; the disease is cancer.